Data collection on CAR T-cells related news

How do I report on patients treated with CAR-T cells to the EBMT Registry? Part 3: Reporting on hypogammaglobulinemia and B-cell aplasia

15 JUNE 2020

How do I report on patients treated with CAR-T cells to the EBMT Registry? Part 2: Capturing essential information on the cytokine release syndrome (CRS) and Immune Cells Associated Neurotoxicity Syndrome (ICANS).

15 OCTOBER 2020

EBMT to track long-term outcome data for Yescarta®, a CAR T therapy for adults living with two types of aggressive non-Hodgkin lymphoma

2 JUNE 2020

How do I report on patients treated with CAR-T cells to the EBMT Registry? Part 1: Capturing essential information on the manufactured medicinal product

28 FEBRUARY 2020

EBMT to track long-term outcome data for Kymriah®

10 FEBRUARY 2020

A growing community: CAR-T cells activities in Europe

28 JANUARY 2020

EBMT centre members and national registries are requested to document CAR T cell therapies

30 SEPTEMBER 2019

Registration of CAR-T Cellular therapies in EBMT Registry

19 JUNE 2019

Important change to MED-A forms for Cellular Therapy

11 MARCH 2019

EBMT receives a regulatory qualification from the European Medicine Agency (EMA) on the use of its patient registry to support novel CAR T-cell therapies.

1 MARCH 2019